Search: WFRF:(Bax Jeroen)
> (2020-2024) >
Development, valida...
Development, validation and implementation of biomarker testing in cardiovascular medicine state-of-the-art : Proceedings of the European Society of Cardiology - Cardiovascular Round Table
-
Elliott, Perry (author)
-
Cowie, Martin R. (author)
-
Franke, Jennifer (author)
-
show more...
-
Ziegler, André (author)
-
Antoniades, Charalambos (author)
-
Bax, Jeroen (author)
-
Bucciarelli-Ducci, Chiara (author)
-
- Flachskampf, Frank A., 1957- (author)
- Uppsala universitet,Klinisk fysiologi,Kardiologi
-
Hamm, Christian (author)
-
Jensen, Magnus T. (author)
-
Katus, Hugo (author)
-
Maisel, Alan (author)
-
McDonagh, Theresa (author)
-
Mittmann, Clemens (author)
-
Muntendam, Pieter (author)
-
Nagel, Eike (author)
-
Rosano, Giuseppe (author)
-
Twerenbold, Raphael (author)
-
Zannad, Faiez (author)
-
show less...
-
(creator_code:org_t)
- 2020-09-22
- 2021
- English.
-
In: Cardiovascular Research. - : Oxford University Press. - 0008-6363 .- 1755-3245. ; 117:5, s. 1248-1256
- Related links:
-
https://academic.oup...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Many biomarkers that could be used to assess ejection fraction, heart failure, or myocardial infarction fail to translate into clinical practice because they lack essential performance characteristics or fail to meet regulatory standards for approval. Despite their potential, new technologies have added to the complexities of successful translation into clinical practice. Biomarker discovery and implementation requires a standardised approach that includes: identification of a clinical need; identification of a valid surrogate biomarker; stepwise assay refinement, demonstration of superiority over current standard-of-care; development and understanding of a clinical pathway; and demonstration of real-world performance. Successful biomarkers should improve efficacy or safety of treatment, while being practical at a realistic cost. Everyone involved in cardiovascular healthcare, including researchers, clinicians, and industry partners, are important stakeholders in facilitating the development and implementation of biomarkers. This paper provides suggestions for a development pathway for new biomarkers, discusses regulatory issues and challenges, and suggestions for accelerating the pathway to improve patient outcomes. Real life examples of successful biomarkers-high sensitivity cardiac troponin (hs-cTn), T2* cardiovascular magnetic resonance (CMR) imaging, and echocardiography-are used to illustrate the value of a standardised development pathway in the translation of concepts into routine clinical practice.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- biomarker
- ejection fraction
- heart failure
- magnetic resonance
- myocardial infarction
- pathway
- troponin
- Kardiologi
- Cardiology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Elliott, Perry
-
Cowie, Martin R.
-
Franke, Jennifer
-
Ziegler, André
-
Antoniades, Char ...
-
Bax, Jeroen
-
show more...
-
Bucciarelli-Ducc ...
-
Flachskampf, Fra ...
-
Hamm, Christian
-
Jensen, Magnus T ...
-
Katus, Hugo
-
Maisel, Alan
-
McDonagh, Theres ...
-
Mittmann, Clemen ...
-
Muntendam, Piete ...
-
Nagel, Eike
-
Rosano, Giuseppe
-
Twerenbold, Raph ...
-
Zannad, Faiez
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
Cardiovascular R ...
- By the university
-
Uppsala University